Multiple Sclerosis Clinical Trials in Birmingham, Alabama

6 studies are recruiting for multiple sclerosis in Birmingham, Alabama right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

   The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

   Stage

   Not phased

   Ages

   18 and older

   Site

   TG Therapeutics Investigational Trial Site, Birmingham, Alabama

   Locations

   113 in total

   Run by

   TG Therapeutics, Inc.

   See if you can join NCT06433752 on ClinicalTrials.gov

2. A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

   The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or …

   Stage

   Phase 4

   Ages

   18 to 65

   Site

   Alabama Neurology Associates, Birmingham, Alabama

   Locations

   8 in total

   Run by

   Genentech, Inc.

   See if you can join NCT07609719 on ClinicalTrials.gov

3. Care in Multiple Sclerosis (MS)

   This study is structured around three main aims. In Aim 1, investigators will conduct community-based participatory research (CBPR) to develop culturally tailored methods to assess childhood adversity in multiple sclerosis (MS). Aim 2 will investigate the impact of childhood adversity on MS outcome…

   Stage

   Not phased

   Ages

   18 to 29

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   6 in total

   Run by

   NYU Langone Health

   See if you can join NCT07011914 on ClinicalTrials.gov

4. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

   This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03816345 on ClinicalTrials.gov

5. Understanding the Impact of Meal Timing on Neurological Health in Adults With Multiple Sclerosis

   The goal of this clinical trial is to learn if the time an individual eats each day impacts neurological health in people with multiple sclerosis. The main questions the investigators are asking are: 1. Does meal timing affect biomarkers of neuronal health (neurofilament light chain [NfL] and BDNF)…

   Stage

   Not phased

   Ages

   18 to 64

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT07475377 on ClinicalTrials.gov

6. Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

   The primary objective of this study is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET radiopharmaceutical [F-18]DPA-714 in individuals with chronic pain and fatigue suspected to be associated with neuroinflammation. The PET tr…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   University of Alabama at Birmingham Medical Center, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT03759522 on ClinicalTrials.gov